Abstract
Aripiprazole possesses a complex pharmacology with both partial agonist and full antagonist effects. The purpose of this article is to critically review, in the light of its unique receptor pharmacology, the current clinical literature on the use of aripiprazole in the treatment of schizophrenia and mood disorders. There is evidence that aripiprazole is an effective and well tolerated antipsychotic in treating schizophrenia. Now, more recent evidence suggests that aripiprazole may have a role in the treatment of mood disorders. The efficacy side-effect profile of aripiprazole is reviewed herein.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
